News Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
3.42 ^USD	0.00%		-5.79%	-20.28%

04-03	Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	MT
04-03	Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	04-04	PU
Piper Sandler Trims Price Target on Sutro Biopharma to $11 From $12, Maintains Overweight Rating	04-03	MT
Truist Securities Adjusts Price Target on Sutro Biopharma to $18 From $25, Keeps Buy Rating	04-03	MT
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	04-02	AQ
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	04-02	CI
Ipsen: worldwide licensing agreement with Sutro Biopharma	04-02	CF
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	04-02	MT
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	03-26	DJ
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating	03-26	MT
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	03-25	AQ
Sutro Biopharma to Participate in Upcoming Investor Conferences	02-06	AQ
Transcript : Sutro Biopharma, Inc. - Special Call	01-04
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	01-04	AQ
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	01-04	CI
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR-targeted ADC, on January 4, 2024	12-15	AQ
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index	12-15	CI
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	12-14	AQ
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed, Refractory CBF/GLIS Presented at ASH 2023	12-12	AQ
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	12-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Summary

Filters